/RGIN
RGIN Stock - Regenicin, Inc.
Healthcare|BiotechnologyOTC
$0.00+100.00%
+$0.00 (+100.00%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RGIN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.27
52W High$0.75
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-601,000 | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-601,000 | $-635,864 | $-511,000 | $-737,000 | $-540,000 |
| Net Income | $-639,000 | $-670,602 | $-560,000 | $-758,000 | $-559,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-0.00 |
Company Overview
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RGINBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q2 2023
EPS Surprise History
Q3 21
No data
Q1 22
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q1 23
No data
Q1 23
No data
Q2 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 15, 2023 | — | $-0.00 | — | — |
Q1 2023 | Feb 13, 2023 | — | $-0.00 | — | — |
Q1 2023 | Jan 13, 2023 | — | $-0.00 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.00 | — | — |
Q2 2022 | May 23, 2022 | — | $-0.00 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-0.00 | — | — |
Q1 2022 | Jan 13, 2022 | — | $-0.00 | — | — |
Q3 2021 | Aug 23, 2021 | — | $-0.00 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.00 | — | — |
Q1 2021 | Feb 22, 2021 | — | $-0.00 | — | — |
Q1 2021 | Jan 13, 2021 | — | $-0.00 | — | — |
Q3 2020 | Aug 19, 2020 | — | $-0.00 | — | — |
Q2 2020 | May 20, 2020 | — | $-0.00 | — | — |
Q1 2020 | Feb 19, 2020 | — | $-0.00 | — | — |
Q1 2020 | Jan 14, 2020 | — | $-0.00 | — | — |
Q3 2019 | Aug 19, 2019 | — | $-0.00 | — | — |
Q2 2019 | May 20, 2019 | — | $-0.00 | — | — |
Q1 2019 | Feb 19, 2019 | — | $-0.00 | — | — |
Q1 2019 | Jan 15, 2019 | — | $0.00 | — | — |
Q3 2018 | Aug 14, 2018 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about RGIN
What is RGIN's current stock price?
Regenicin, Inc. (RGIN) is currently trading at $0.00 per share. The stock has moved +100.00% today.
What is the analyst price target for RGIN?
No analyst price targets are currently available for this stock.
What sector is Regenicin, Inc. in?
Regenicin, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is RGIN's market cap?
Regenicin, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does RGIN pay dividends?
No, Regenicin, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAOLS
Aeolus Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
NNLX
NanoLogix, Inc.
$0.00
Mkt Cap: $0.0B
OZYMF
Strategic Partners A/S
$90.00
Mkt Cap: $0.0B
PARD
Poniard Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
QBIO
Q BioMed Inc.
$0.00
Mkt Cap: $0.0B
RCAR
RenovaCare, Inc.
$0.00
Mkt Cap: $0.0B
SCPS
Scopus BioPharma Inc.
$0.00
Mkt Cap: $0.0B
VAXX
Vaxxinity, Inc.
$0.00
Mkt Cap: $0.0B
VOQP
VioQuest Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
XSNX
NovAccess Global Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to RGIN for comparison